Management has decided to maintain its full-year 2025 guidance, consistent with previous announcements. In another development, Goldman Sachs initiated coverage of Havas with a Buy rating and set a price target of EUR1.90. The firm highlighted Havas' promising risk/reward profile and potential for earnings growth. Goldman Sachs pointed to the company's strong geographic and category exposure, including 29% of its revenue from the Health sector, as key strengths. Additionally, Havas' net new business and solid balance sheet were noted as positive indicators. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.